Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
  • C07D207/50—Nitrogen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
  • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
  • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
  • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
  • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
  • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
  • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
  • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/06—Phosphorus compounds without P—C bonds
  • C07F9/08—Esters of oxyacids of phosphorus
  • C07F9/09—Esters of phosphoric acids
  • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/07—Optical isomers
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
  • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
  • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
  • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

• the present invention also provides a compound of Formula (I) and/or a pharmaceutically acceptable salt thereof, for use in therapy.
• the compounds of Formula (III) and/or salts thereof, are useful as prodrugs of the compounds of Formula (II).
• the compounds of Formula (III) are activated in vivo through phosphorylation to provide the compounds of Formula (II).
• the compounds of Formula (II) are active as a selective agonists of S IPi.
• One embodiment provides the compound of Formula (III) as a salt selected from
• One embodiment provides a compound selected from ((lR,3R)-l-amino-3-((R)-6- hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate and ((lR,3S)-l-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate; and salts thereof.
• a pharmaceutical composition comprises substantially pure Form N-1 of Example 2; and at least one pharmaceutically-acceptable carrier and/or diluent.
• a therapeutically effective amount of Form N- 1 of Example 2 is combined with at least one pharmaceutically acceptable carrier and/or diluent to provide at least one pharmaceutical composition.
• a substantially pure second crystalline form has substantially pure phase homogeneity with less than about 10%, preferably less than about 5%, and more preferably less than about 2% of the total peak area of the experimentally measured PXRD pattern arising from peaks that are absent from the simulated PXRD pattern. Most preferably, a substantially pure second crystalline form has substantially pure phase homogeneity with less than about 1% of the total peak area of the experimentally measured PXRD pattern arising from peaks that are absent from the simulated PXRD pattern.
• the H-2 Form of Example 2 HCl salt is substantially pure.
• the H-2 Form of Example 2 HCl salt contains at least about 90 wt.%, preferably at least about 95 wt.%, and more preferably at least about 99 wt.%, based on weight of the third crystalline form.
• the N-4 Form of the HC1 salt of Example 2 is substantially pure.
• N-4 of Example 2 is combined with at least one pharmaceutically acceptable carrier and/or diluent to provide at least one pharmaceutical composition.
• the H-1 Form of the hemi-malonic acid salt of Example 2 is characterized by unit cell parameters approximately equal to the following:
• the H-1 form of the hemi-malonic acid salt of Example 2 is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 7 and/or by an observed PXRD pattern substantially in accordance with the pattern shown in Figure 7.
• PXRD powder x-ray diffraction
• the Example 2 is provided as a phosphoric acid salt.
• the Example 2 is provided as a 1/3 -hydrate phosphoric acid salt.
• Example 2 is provided as a phosphoric acid salt comprising 0.67 mole of phosphoric acid for each mole of Example 2.
• Example 2 is provided as a 1/3-hydrate phosphoric acid salt comprising 0.33 mole of water and 0.67 mole of phosphoric acid for each mole of Example 2.
• the H.33-1 Form is characterized by unit cell parameters approximately equal to the following:
• the H.33-1 form of the 1/3-phosphoric acid salt of Example 2 is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 8 and/or by an observed PXRD pattern substantially in accordance with the pattern shown in Figure 8.
• PXRD powder x-ray diffraction
• the Example 2 is provided as an R-(+)-mandelic acid salt. In one embodiment, the Example 2 is provided as a monohydrate R-(+)-mandelic acid.
• the monohydrate R-(+)-mandelic acid salt of Example 2 is provided in an ninth crystalline form referred to herein as "Form N-l" or "N-l Form” of Example 2, R-(+)-mandelic acid salt.
• the N- 1 Form of Example 2, R-(+)-mandelic acid salt comprises one molecule of water and one molecule of R-(+)-mandelic acid for each molecule of Example 2.
• the unit cell parameters of Form N-1 of Example 2, R-(+)-mandelic acid salt measured at a temperature of about -70 °C.
• the N-1 Form of Example 2, R-(+)-mandelic acid salt is characterized by a simulated powder x-ray diffraction (PXRD) pattern substantially in accordance with the pattern shown in Figure 9.
• any atom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.
• Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
• lower alkyl halides e.g., methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
• dialkyl sulfates e.g., dimethyl, diethyl, dibutyl, and diamyl sulfates
• composition may be administered as an oral dosage form or an infusion, for example.
• the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid.
• the pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient.
• the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, and more preferably from about 0.5 to 100 mg.
• a suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, can be determined using routine methods.
• a tablet can, for example, be prepared by admixing at least one compound of
• a tablet can either be uncoated, or coated by known techniques to either mask the bad taste of an unpleasant tasting drug, or delay disintegration and absorption of the active ingredient in the gastrointestinal tract thereby sustaining the effects of the active ingredient for a longer period.
• exemplary water soluble taste masking materials include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl- cellulose.
• Exemplary time delay materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.
• excipients suitable for the manufacture of an aqueous suspension include, but are not limited to, for example, suspending agents, such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, alginic acid, polyvinyl-pyrrolidone, gum tragacanth, and gum acacia; dispersing or wetting agents, such as, for example, a naturally-occurring phosphatide, e.g., lecithin; condensation products of alkylene oxide with fatty acids, such as, for example, polyoxy ethylene stearate; condensation products of ethylene oxide with long chain aliphatic alcohols, such as, for example heptadecaethylene-oxycetanol; condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate; and condensation products of ethylene oxide with partial esters derived from fatty acids and hexi
• An emulsion of at least one compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof can, for example, be prepared as an oil-in- water emulsion.
• the oily phase of the emulsions comprising compounds of Formula (I) may be constituted from known ingredients in a known manner.
• the oil phase can be provided by, but is not limited to, for example, a vegetable oil, such as, for example, olive oil and arachis oil; a mineral oil, such as, for example, liquid paraffin; and mixtures thereof. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
• the compounds of the present invention are immunoregulatory agents useful for treating or preventing autoimmune or chronic inflammatory diseases.
• the compounds of the present invention are useful to suppress the immune system in instances where immunosuppression is in order, such as in bone marrow, organ or transplant rejection, autoimmune and chronic inflammatory diseases, including systemic lupus erythematosis, rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves' ophthalmopathy, and asthma.
• a method for treating inflammatory bowel disease comprising administering to a mammal in need thereof at least one compound of Formula (I) or a pharmaceutically acceptable salt thereof.
• Another embodiment provides the compounds of Formula (I) or pharmaceutically acceptable salts thereof, for use in therapy for the treatment of inflammatory bowel disease.
• a therapeutically effective amount may be employed in these embodiments.
• Condition I Column: Waters Acquity SD BEH C 18, 2.1 x 50 mm, 1.7- ⁇ particles; Mobile Phase A: 100%H 2 O with 0.05%TFA; Mobile Phase B: 100% acetonitrile with 0.05% TFA; Temperature: 50 °C; gradient of 98:2 to 2:98 (A%:B%) over 1 min and hold 2:98 for 0.5 min.; Flow: 0.800 mL/min Products detected at 220 nm.
• CCVMeOH 70/30; Detector Wavelength: 220nm; Injection Vol.: 5 ⁇ .
• the desired enantiomer (major isomer) was isolated and named as "PK2" based on the elution order.
• reaction mixture was stirred for 30 minutes then l, l, l-trifluoro-N-phenyl-N-(trifluoromethyl)sulfonyl methanesulfonamide (639 mg, 1.787 mmol) in THF (10 mL) was added.
• THF 10 mL
• the reaction mixture was warmed to 0 °C. After 1 hour, the reaction was quenched with water.
• the reaction mixture was diluted with ethyl acetate and washed with saturated aqueous NaCl. The organic layer was dried with MgS0 4 , filtered and concentrated.
• the resulting brown suspension was stirred at 0 °C for 30 min and at room temperature for 1 h.
• the mixture was extracted with ethyl acetate (400 mL, 2 x 100 mL).
• the combined ethyl acetate extracts were washed with water (60 mL), saturated aqueous a 2 S203 solution until the brown color disappeared, and saturated aqueous K 3 PO 4 (60 mL) solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
• dichloromethane (15 mL) was stirred at room temperature for 1 day. Additional 7 M methanol solution of ammonia (15 mL) was added. The mixture was stirred at room temperature for 1 day and then concentrated. The residue was partitioned between ethyl acetate (70 mL) and saturated aqueous sodium bicarbonate solution (100 mL). The aqueous layer was separated and extracted with ethyl acetate (3 x 50 mL).
• the solid was dissolved in methanol (20 mL) and mixed with toluene (20 mL). The mixture was concentrated to dryness. This drying procedure was repeated one more time to give a dry solid.
• the solid was dissolved in anhydrous methanol (300 mL).
• Thionyl chloride (1 1.66 mL, 160 mmol) was added dropwise at 0 °C under nitrogen. The reaction mixture was stirred at 70 °C for 7 h before being concentrated.
• the residue was made basic with saturated aqueous sodium bicarbonate solution (100 mL) and some potassium carbonate solid and extracted with ethyl acetate (100 mL, 3 x 30 mL).
• reaction mixture was stirred for 15 minutes, and then ferric acetylacetonate (0.042 g, 0.120 mmol) and hexylmagnesium bromide in ether (2.396 mL, 4.79 mmol) were added.
• the reaction mixture was stirred for 30 minutes and quenched with water.
• the reaction mixture was diluted with ethyl acetate and washed with 1M HCl. The organic layer was dried with MgS0 4 , filtered and concentrated.
• the reaction mixture was filtered and concentrated in vacuo.
• the crude material was purified on a silica gel cartridge (40 g) using an EtOAc/hexane gradient (0-100% EtOAc over 20 minutes) to afford 640 mg of (5R,7S)-7-(6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3- oxa-l-azaspiro[4.4]nonan-2-one in a 1 :2 ratio of the two isomers.
• the crude material was purified on a silica gel cartridge (24 g) using an 20% (2N NH 3 /MeOH) in DCM/DCM gradient (0-75% of 20% (2N NH 3 /MeOH) in DCM over 13 CV) to afford 290 mg of ((lR,3S)-l-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2- yl)cyclopentyl)methanol.
• the monohydrate, mono-HCl salt of Example 2 Form H-2 was obtained by preparing a 50:50 aqueous THF (200 ⁇ 1) solution containing 3.2 mg of Example 2. Next, 400 ⁇ 1 of a 0.025M aqueous HCl solution was added dropwise with stirring. The solution was then evaporated to yield plates of the monohydrate H-2 form of the mono-HCl salt of Example 2.
• the mono-HCl salt of Example 2 Form N-3 was obtained by preparing a 200 ⁇ 1 solution of isopropyl alcohol containing 3.2 mg of Example 2. Next, a 400 ⁇ of a 0.025 M alcoholic HCl solution was added dropwise with stirring. The solution was evaporated to yield plates of the N-3 form of the mono-HCl salt of Example 2.
• the monohydrate, hemi-L-malic acid salt, Form H-l was obtained by preparing a 200 ⁇ 50:50 aqueous THF solution containing 3.2 mg of Example 2. Next, 240 ⁇ 1 of a 0.042 M alcoholic L-malic acid solution was added dropwise with stirring. The resulting solution was evaporated to yield plates of the H-l form of the hemi-L-malic acid salt of Example 2.
• the monohydrate, hemi-malonic acid salt, Form H-l was obtained by preparing a 200 ⁇ 50:50 aqueous THF solution containing 3.2 mg of Example 2. Next, 193 ⁇ of a 0.052 M alcoholic malonic acid solution was added dropwise with stirring. The resulting solution was evaporated to yield plates of the H-l form of the hemi-malonic acid salt of Example 2.
• Example 2, 1/3-Hydrate, Phosphoric Acid Salt, Form H.33-1
• the 1/3-hydrate, phosphoric acid salt, Form H.33-1 was obtained by preparing a 200 ⁇ 50:50 aqueous methanol solution containing 3.2 mg of Example 2. Next, 136 ⁇ of a 0.073 M alcoholic phosphoric acid solution was added dropwise with stirring. The resulting solution was evaporated to yield plates of the H.33-1 form of the phosphoric acid salt of Example 2.
• the reaction mixture was stirred at 40 °C for 18 h.
• the solution was cooled to 0 °C before hydrogen peroxide (0.781 mL, 7.82 mmol) was added.
• the mixture was stirred at 0 °C for 30 minutes at room temperature for 1 h before methanol (3 mL) was added to make the mixture a homogeneous solution.
• the solution was stirred at room temperature for 1 h.
• a saturated aqueous sodium thiosulfate solution (5 mL) was added to quench the reaction.
• the mixture was concentrated under reduced pressure and extracted with ethyl acetate (3 x 4 mL).
• the combined organic solutions were dried (Na 2 S0 4 ) and concentrated under reduced pressure.
• Detector Wavelength UV 200-400 nm.
• lymphocytes without increasing in the BAL protein without increasing in the BAL protein, a measure of pulmonary side effects.
• the exemplified compounds of the invention reported in Table 4b and 5 reduced the blood lymphocytes by 88% and 90%, and gave relative BAL protein levels of 0.99 and 0.96, respectively, which indicated no increase in pulmonary side effects.
• Compound 6 and Comparative Compound 11 reduced blood lymphocytes by 78% and 52%, and gave relative BAL protein levels of 1.96 and 1.33, respectively, indicating increased risk of pulmonary side effects.
• Compound 8 reduced blood lymphocytes by 59% and gave relative BAL protein levels of 1.03, which indicated no or slight increase in pulmonary side effects.
• the compounds of the present invention possess activity as agonists of the SlPi receptor, leading to the reduction of circulating blood lymphocytes, and thus may be used in treating, preventing, or curing various SlPi receptor-related conditions while reducing or minimizing pulmonary side effects, such as pulmonary edema.
• the surprising selectivity of the compounds of the present invention indicate their potential use in treating, preventing, or curing autoimmune and inflammatory diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases, lupus, or psoriasis, while reducing or minimizing possible pulmonary side effects.
• Other potential uses of the compounds of the present invention include minimizing or reducing rejection of transplanted organs, while reducing or minimizing possible pulmonary side effects.
• the mouse T Cell transfer induced colitis assay is an animal model for human colitis.
• Example 2 was tested in the mouse T cell transfer induced colitis model described hereinabove and the results are shown in Table 8.
• the compound of this invention as exemplified by Example 2, in the reported test, showed inhibition of disease progression as measured by reduced body weight loss or increase body weight, and a reduction in inflammation and damage in the mouse T Cell transfer induced colitis assay.
• MRL/lpr mouse model of spontaneous lupus erythematosus assay is an animal model for spontaneous lupus erythematosus.
• Urine protein levels (by Albustix) were measured on day 0 and throughout the study.
• Table 9 indicates the percentage of mice in each treatment groups that demonstrated high levels of proteinurea (greater than 100 mg/dL) at 25 weeks of age. Additional groups of mice received a daily oral dose of dexamethasone (Dex) either independently or in combination with twice weekly dosing with Example 2.
• Urine protein levels by Albustix were measured on day 0 and throughout the study.
• Table 9 indicates the percentage of mice in each treatment groups that demonstrated high levels of proteinurea (greater than 100 mg/dL) at 24 weeks of age. All procedures involving animals were reviewed and approved by the Institutional Animal Care Use Committee.
• Example 2 was tested in the MRL/lpr mouse model of spontaneous lupus erythematosus assay described hereinabove and the results are shown in Table 9.
• Example 2 and dexamethasone (Dex) either independently or in combination were tested in the MRL/lpr mouse model of spontaneous lupus erythematosus assay described hereinabove and the results are shown in Table 10. Both the compound of this invention, as exemplified by Example 2, and dexamethasone in the reported test, showed inhibition of disease progression as measured by a lower percentage of mice with a proteinurea level of greater than 100 mg/mL. In this test, no mice administered the combination of Example 2 and dexamethasone had a proteinurea level of greater than 100 mg/mL.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Transplantation (AREA)
• Dermatology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Heart & Thoracic Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Cardiology (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Epidemiology (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Indole Compounds (AREA)

Priority Applications (24)

Applications Claiming Priority (2)

Publications (2)

Family

ID=50272738

Family Applications (1)

Country Status (34)

Cited By (5)

Families Citing this family (3)

Citations (24)

Family Cites Families (33)

• 2014
  • 2014-02-20 UY UY0001035338A patent/UY35338A/es unknown
  • 2014-02-20 US US14/185,164 patent/US9115054B2/en active Active
  • 2014-02-20 TW TW103105719A patent/TWI613182B/zh not_active IP Right Cessation
  • 2014-02-21 CA CA2902168A patent/CA2902168C/en not_active Expired - Fee Related
  • 2014-02-21 EP EP14709822.2A patent/EP2958888B1/en active Active
  • 2014-02-21 HU HUE14709822A patent/HUE031626T2/en unknown
  • 2014-02-21 PT PT147098222T patent/PT2958888T/pt unknown
  • 2014-02-21 HR HRP20170247TT patent/HRP20170247T1/hr unknown
  • 2014-02-21 MA MA38425A patent/MA38425B1/fr unknown
  • 2014-02-21 RS RS20170188A patent/RS55703B1/sr unknown
  • 2014-02-21 ES ES14709822.2T patent/ES2613262T3/es active Active
  • 2014-02-21 PL PL14709822T patent/PL2958888T3/pl unknown
  • 2014-02-21 JP JP2015558976A patent/JP6277210B2/ja not_active Expired - Fee Related
  • 2014-02-21 MX MX2015010347A patent/MX2015010347A/es unknown
  • 2014-02-21 AR ARP140100554A patent/AR094851A1/es unknown
  • 2014-02-21 WO PCT/US2014/017534 patent/WO2014130752A2/en not_active Ceased
  • 2014-02-21 MY MYPI2015702746A patent/MY173990A/en unknown
  • 2014-02-21 LT LTEP14709822.2T patent/LT2958888T/lt unknown
  • 2014-02-21 CN CN201480009497.1A patent/CN105026362B/zh active Active
  • 2014-02-21 BR BR112015019919A patent/BR112015019919A2/pt not_active Application Discontinuation
  • 2014-02-21 EA EA201591409A patent/EA025294B1/ru not_active IP Right Cessation
  • 2014-02-21 SI SI201430106A patent/SI2958888T1/sl unknown
  • 2014-02-21 KR KR1020157025410A patent/KR102242265B1/ko not_active Expired - Fee Related
  • 2014-02-21 SM SM20170115T patent/SMT201700115T1/it unknown
  • 2014-02-21 SG SG11201506408TA patent/SG11201506408TA/en unknown
  • 2014-02-21 AU AU2014218883A patent/AU2014218883B2/en not_active Ceased
  • 2014-02-21 PE PE2015001795A patent/PE20151746A1/es active IP Right Grant
  • 2014-02-21 DK DK14709822.2T patent/DK2958888T3/en active
• 2015
  • 2015-07-14 US US14/798,498 patent/US9359286B2/en active Active
  • 2015-08-14 PH PH12015501793A patent/PH12015501793A1/en unknown
  • 2015-08-17 IL IL240613A patent/IL240613B/en active IP Right Grant
  • 2015-08-18 TN TN2015000356A patent/TN2015000356A1/en unknown
  • 2015-08-21 CL CL2015002358A patent/CL2015002358A1/es unknown
  • 2015-09-18 ZA ZA2015/06965A patent/ZA201506965B/en unknown
• 2016
  • 2016-05-06 US US15/148,222 patent/US9487481B2/en active Active
• 2017
  • 2017-02-16 CY CY20171100216T patent/CY1118641T1/el unknown
  • 2017-02-21 SM SM201700115T patent/SMT201700115B/it unknown

Patent Citations (30)

Non-Patent Citations (14)

Also Published As

Similar Documents

Legal Events